Guardant Health (GH) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
8 Jul, 2026Opening remarks and agenda
The meeting was called to order by the Co-CEO and Chairperson, conducted virtually to maximize accessibility for stockholders.
Rules of conduct and agenda were made available on the web portal, with procedures for voting and asking questions clearly outlined.
Only stockholders of record as of April 15, 2024, were eligible to participate and vote.
Board and executive committee updates
The Board of Directors and key executives, including the Co-CEOs and other board members, were present.
Representatives from Deloitte & Touche LLP (auditors) and Gunderson Dettmer (legal counsel) also attended.
Overview of voting outcomes
A quorum was established with proxies for over 97 million shares, representing 79.7% of outstanding shares.
All three Class 3 director nominees were elected by plurality vote.
Ratification of Deloitte & Touche LLP as independent auditors for 2024 was approved by majority vote.
Advisory approval of executive compensation received a majority of votes cast.
Final voting results will be filed with the SEC on Form 8-K within four days.
Latest events from Guardant Health
- Multi-cancer early detection is poised to transform cancer care, reducing mortality and costs.GH
7th Annual Healthcare Symposium14 Jul 2026 - 2028 revenue target raised to ~$2.2B, with accelerated breakeven and major product launches.GH
Investor Day 20259 Jul 2026 - Q3 revenue up 34% to $191.5M; Shield launch, ASP gains, and raised guidance highlight growth.GH
Q3 20248 Jul 2026 - Strong growth and innovation, with regulatory and commercial catalysts set to drive 2026 performance.GH
TD Cowen 46th Annual Health Care Conference8 Jul 2026 - 2025 revenue up 33% year-over-year, with robust outlook and innovation driving 2026 growth.GH
Q4 20258 Jul 2026 - 31% revenue growth, margin gains, and Shield's FDA approval drive strong 2025 outlook.GH
Q4 20248 Jul 2026 - Q2 revenue up 29% to $177.2M; Shield test FDA approved; 2024 guidance raised to $690–$700M.GH
Q2 20248 Jul 2026 - All proposals passed, directors elected, and no stockholder questions were raised.GH
AGM 202617 Jun 2026 - Rapid innovation and Shield adoption drive strong growth, targeting FCF breakeven by Q4 2027.GH
46th Annual William Blair Growth Stock Conference8 Jun 2026